Supernus Pharmaceuticals SG&A Expenses 2011-2024 | SUPN

Supernus Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Supernus Pharmaceuticals Annual SG&A Expenses
(Millions of US $)
2023 $336
2022 $377
2021 $305
2020 $201
2019 $153
2018 $155
2017 $138
2016 $106
2015 $89
2014 $73
2013 $56
2012 $20
2011 $8
2010 $5
Supernus Pharmaceuticals Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $86
2024-03-31 $87
2023-12-31 $81
2023-09-30 $83
2023-06-30 $87
2023-03-31 $86
2022-12-31 $74
2022-09-30 $112
2022-06-30 $100
2022-03-31 $90
2021-12-31 $102
2021-09-30 $72
2021-06-30 $70
2021-03-31 $61
2020-12-31 $57
2020-09-30 $54
2020-06-30 $48
2020-03-31 $42
2019-12-31 $33
2019-09-30 $39
2019-06-30 $40
2019-03-31 $41
2018-12-31 $37
2018-09-30 $41
2018-06-30 $40
2018-03-31 $37
2017-12-31 $34
2017-09-30 $41
2017-06-30 $35
2017-03-31 $28
2016-12-31 $29
2016-09-30 $26
2016-06-30 $26
2016-03-31 $25
2015-12-31 $24
2015-09-30 $23
2015-06-30 $23
2015-03-31 $19
2014-12-31 $18
2014-09-30 $17
2014-06-30 $20
2014-03-31 $18
2013-12-31 $15
2013-09-30 $15
2013-06-30 $12
2013-03-31 $14
2012-12-31 $9
2012-09-30 $4
2012-06-30 $5
2012-03-31 $3
2011-12-31 $3
2011-09-30 $2
2011-06-30 $2
2011-03-31 $2
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.022B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00